Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has signed a strategic collaboration agreement with a Nasdaq-listed biopharma company for the development of an optimised oral drug to treat a metabolic condition.
Under the agreement, the company will receive funding to work with its new partner to produce a prototype drug utilising Poolbeg’s licensed oral delivery technology.
Our partner recognises the benefits of Poolbeg’s licensed oral delivery technology and we look forward to optimising the development of this innovative drug for patients in an area where there is a clear unmet need
Jeremy Skillington, CEO of Poolbeg Pharma
Poolbeg has an exclusive licence to patented oral delivery technologies for all metabolic conditions and is utilising the same technology for its Oral GLP-1 agonist programme.
Poolbeg believes that this technology can help to optimise the delivery of its partner’s novel drug to its ideal site of therapeutic action.
The company is optimistic that this strategic collaboration can progress to a full licensing agreement in time, whereby the Nasdaq-listed biopharma could integrate this novel oral delivery technology into its pipeline.
This marks another significant milestone in Poolbeg's journey towards early revenues and underscores the Company's commitment to advancing treatments for metabolic conditions.
Jeremy Skillington, CEO of Poolbeg Pharma, said: “Our partner recognises the benefits of Poolbeg’s licensed oral delivery technology and we look forward to optimising the development of this innovative drug for patients in an area where there is a clear unmet need. We are optimistic that this strategic collaboration has the potential to progress to a full licensing agreement.”
